Market cap
$2 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
0
P/B Ratio
0.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -108.48 | 88.28 | 67.70 | -274.66 | -257.02 |
| Net Profit | -105.74 | 88.24 | 66.74 | -265.30 | -435.59 |
| EPS | -22.56 | 43.27 | 89.18 | -153.07 | -126.33 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Jun-25 | Jun-24 |
| EBIT-Margin
| -- | -- | -59,201.15 | -- | -- |
| Net Margin
| -- | -- | -61,399.58 | -- | -- |
| Return on equity
| -341.40 | -175.31 | -151.81 | -1,163.67 | 52.81 |
| Return on Capital
| -245.41 | -105.02 | -- | -920.51 | 67.42 |
| Return on Assets
| -2,363.73 | -3,266.37 | -82.19 | -598.08 | -2,744.68 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.12 | -0.25 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
--
|
-920.51
|
67.42
|
116.85
|
121.63
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-151.81
Lower than Peers by 111.48
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
-151.81
|
-1,163.67
|
52.81
|
86.67
|
87.27
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-82.19
Lower than Peers by 50.95
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
-82.19
|
-598.08
|
-2,744.68
|
-3,748.44
|
-5,610.44
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
-59,201.15
Lower than Peers by 59,118.56
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
-59,201.15
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
-61,399.58
Lower than Peers by 61,308.28
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
-61,399.58
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Cash Profit Margin
-2.85
Lower than Peers by 2.85
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
-2.85
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
EBIT Growth
67.70
Higher than Peers by 68.72
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
67.70
|
-4,446.35
|
43.15
|
-5.46
|
-26.69
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
66.74
Higher than Peers by 74.28
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
66.74
|
-3,135.77
|
31.57
|
-0.11
|
-31.19
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
EPS Growth
89.18
Higher than Peers by 74.95
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
89.18
|
0.98
|
-514.90
|
0.96
|
0.92
|
|
Peer Median
|
14.23
|
--
|
--
|
--
|
--
|
Book Value Growth
161.95
Higher than Peers by 172.08
Year on year growth in book value per share
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
161.95
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.13
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
--
|
0.12
|
-0.25
|
-0.18
|
-0.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.06
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
0.06
|
0.11
|
-0.24
|
-0.17
|
-0.33
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.37
Lower than Peers by 3.44
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
2.37
|
1.50
|
0.01
|
0.01
|
0.00
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
2.37
Lower than Peers by 3.33
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
2.37
|
--
|
--
|
0.01
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-26.93
Lower than Peers by 24.84
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
-26.93
|
-103.52
|
-1.93
|
-4.24
|
-3.76
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
36.97
Higher than Peers by 17.96
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
36.97
|
--
|
--
|
--
|
--
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
0.00
Lower than Peers by 0.06
Sales / Average Total Assets
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
--
|
--
|
-48.35
|
-58.96
|
-279.59
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
--
|
--
|
18,384.38
|
19,637.75
|
62,646.98
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
0.00
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
0.00
|
-0.82
|
-0.16
|
-9,179.09
|
-9,141.88
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.26
Lower than Peers by 5.07
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
0.26
|
3.47
|
-0.08
|
-7,835.79
|
-8,036.35
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
2.90
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
2.90
|
-0.86
|
-0.97
|
-10,928.90
|
-11,360.52
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
2
Lower than Peers by 139
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Propanc Biopharma, Inc. (PPCB)
|
2
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|